Available online on 15.07.2024 at ijmspr.com

International Journal of Medical Sciences and Pharma Research

Open Access to Medical Science and Pharma Research

Copyright  © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Hemochromatosis and HIV: Implications for Disease Progression

Emmanuel Ifeanyi Obeagu *

Department of Medical Laboratory Science, Kampala International University, Uganda. 

 

 

Introduction

Hemochromatosis is a genetic disorder characterized by excessive absorption and accumulation of dietary iron, leading to iron overload in various organs, particularly the liver, heart, and pancreas.¹ The most common form, hereditary hemochromatosis, is usually caused by mutations in the HFE gene, specifically the C282Y and H63D mutations. This iron accumulation can lead to severe complications, including liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiomyopathy. The pathophysiology of hemochromatosis involves dysregulation of hepcidin, a key hormone that controls iron homeostasis by inhibiting intestinal iron absorption and promoting iron sequestration in macrophages. Human immunodeficiency virus (HIV) is a lentivirus that causes acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV primarily targets CD4+ T cells, leading to their depletion and severe immunosuppression. The management of HIV has been revolutionized by the advent of antiretroviral therapy (ART), which, when used consistently, can maintain viral suppression and improve the quality of life for infected individuals. However, HIV remains a significant global health challenge due to its chronic nature, the need for lifelong treatment, and the complex interactions between HIV and various comorbidities.^2-6 The coexistence of hemochromatosis and HIV presents a unique clinical scenario with complex interactions that can influence the progression and management of both conditions. Iron is a critical element for both host and pathogen, playing a significant role in various cellular processes, including DNA synthesis, electron transport, and oxidative phosphorylation. Pathogens, including viruses, can exploit iron for their replication and survival, making iron metabolism a critical factor in infectious diseases.^7-9

In the context of HIV infection, iron metabolism is often disrupted. HIV can induce anemia through various mechanisms, including chronic inflammation, direct bone marrow suppression, and opportunistic infections. Additionally, the virus and the associated inflammatory response can alter hepcidin levels, further complicating iron homeostasis. These disruptions can be particularly problematic in individuals with hemochromatosis, where iron overload is already a significant issue.^10-11 The interplay between hemochromatosis and HIV involves several potential mechanisms. Excessive iron can enhance HIV replication by providing necessary co-factors for viral enzymes and facilitating the generation of reactive oxygen species (ROS), which can activate viral transcription factors. Moreover, iron overload can suppress the immune response, thereby exacerbating the immunosuppressive effects of HIV. This can lead to a more rapid progression of HIV infection and an increased risk of opportunistic infections.^12-14 Regular monitoring of iron levels, liver function, and HIV viral load is essential for co-infected patients. Therapeutic strategies may include phlebotomy or iron chelation to manage iron overload and optimize ART regimens to control HIV replication and mitigate its impact on iron metabolism. Additionally, dietary modifications to limit iron intake and the use of antioxidants to counteract oxidative stress may be beneficial.^15-16 Research into the interaction between iron metabolism and HIV has highlighted the potential for novel therapeutic approaches. Modulating hepcidin levels, using iron chelators, and employing antioxidants could provide new avenues for treatment. These strategies aim to balance the need to reduce iron overload without compromising the immune response necessary to control HIV. The clinical implications of hemochromatosis in HIV-infected individuals extend beyond iron overload and viral replication.^17-18 The combined effects of both conditions can lead to more severe liver disease, including accelerated fibrosis and an increased risk of hepatocellular carcinoma. This necessitates a multidisciplinary approach to patient care, involving hepatologists, infectious disease specialists, and other healthcare providers to address the full spectrum of complications.

Iron Metabolism and Hemochromatosis

Iron is a crucial element required for various physiological processes, including oxygen transport, DNA synthesis, and electron transport. The human body regulates iron homeostasis tightly, as both iron deficiency and iron overload can lead to significant health problems. Iron metabolism involves the absorption, transport, storage, and recycling of iron, ensuring that cellular iron requirements are met without causing toxicity. Iron absorption occurs primarily in the duodenum and upper jejunum of the small intestine.¹⁹ Dietary iron exists in two forms: heme iron, found in animal products, and non-heme iron, found in plant-based foods. Heme iron is absorbed more efficiently than non-heme iron. Once inside the enterocytes, iron can be stored as ferritin or transported into the bloodstream. The absorption process is regulated by several factors, including the body's iron status, hypoxia, and inflammation. A key regulator of iron homeostasis is the hormone hepcidin, which is produced by the liver. Hepcidin controls iron absorption by binding to the iron export protein ferroportin, found on the surface of enterocytes, macrophages, and hepatocytes.²⁰ When hepcidin levels are high, ferroportin is internalized and degraded, reducing iron absorption and mobilization from stores. Conversely, low hepcidin levels increase iron absorption and release from stores. Hemochromatosis is a genetic disorder characterized by excessive iron absorption and accumulation in various organs, leading to iron overload. The most common form, hereditary hemochromatosis, is typically caused by mutations in the HFE gene. The C282Y mutation is the most prevalent, with the H63D mutation also contributing to the disorder. These mutations impair the regulation of hepcidin, leading to decreased hepcidin levels and uncontrolled iron absorption. In hereditary hemochromatosis, the reduced hepcidin levels fail to inhibit ferroportin, resulting in increased iron absorption from the diet and excessive iron release from macrophages and hepatocytes. This leads to a progressive accumulation of iron in the liver, heart, pancreas, and other tissues. Over time, the excess iron generates reactive oxygen species (ROS), causing oxidative stress, inflammation, fibrosis, and organ damage.

Clinical manifestations of hemochromatosis vary depending on the extent and duration of iron overload. Common symptoms include fatigue, joint pain, abdominal pain, and skin hyperpigmentation. If left untreated, hemochromatosis can lead to serious complications such as liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, heart disease, and arthropathy. Early diagnosis and treatment are crucial to prevent these outcomes.²⁰ The diagnosis of hemochromatosis involves a combination of clinical evaluation, blood tests, genetic testing, and imaging studies. Serum ferritin and transferrin saturation are commonly measured to assess iron stores and iron overload. Genetic testing can confirm the presence of HFE mutations. Liver biopsy and imaging studies such as MRI can help evaluate the extent of iron deposition and liver damage. The primary treatment for hemochromatosis is phlebotomy, which involves regular removal of blood to reduce iron levels.²¹ This procedure effectively decreases iron stores and prevents further organ damage. In cases where phlebotomy is not feasible, iron chelation therapy with agents such as deferoxamine may be used to bind and excrete excess iron. Additionally, patients are advised to avoid iron supplements, vitamin C supplements (which increase iron absorption), and excessive dietary iron intake. Management of hemochromatosis requires a multidisciplinary approach, involving primary care physicians, hematologists, hepatologists, cardiologists, and other specialists as needed. Regular monitoring of iron levels, liver function, and other organ functions is essential to ensure effective treatment and prevent complications. Genetic counseling may also be recommended for affected individuals and their families.

HIV and Iron Homeostasis

Human Immunodeficiency Virus (HIV) is a retrovirus that primarily targets CD4+ T cells, leading to progressive immunodeficiency and increased susceptibility to opportunistic infections. The interaction between HIV and iron homeostasis is complex and multifaceted, with significant implications for disease progression and patient management. HIV infection can disrupt iron metabolism through various mechanisms, contributing to both iron deficiency and iron overload in different contexts.^22-23 Iron homeostasis in the body is tightly regulated to balance the essential functions of iron with its potential toxicity. The key regulator of iron homeostasis is the hormone hepcidin, which is produced by the liver in response to iron levels, inflammation, and other signals. Hepcidin controls the absorption of dietary iron and the release of iron from macrophages and hepatocytes by binding to the iron export protein ferroportin and inducing its degradation. This prevents excess iron from entering the bloodstream and accumulating in tissues. In HIV infection, iron homeostasis is often disrupted by the chronic inflammatory state induced by the virus. Inflammatory cytokines, particularly interleukin-6 (IL-6), stimulate hepcidin production, leading to increased internalization and degradation of ferroportin. This results in decreased iron absorption from the intestine and sequestration of iron within macrophages and hepatocytes, contributing to anemia of chronic disease. Anemia is a common complication in HIV-infected individuals and is associated with increased morbidity and mortality.^24-25 Conversely, some studies suggest that HIV-infected individuals can also experience iron overload, particularly in the context of co-infections such as hepatitis C virus (HCV) or as a side effect of certain antiretroviral therapies (ART).²⁶ Iron overload in these patients can exacerbate oxidative stress and tissue damage, further compromising immune function. Elevated levels of free iron can promote the generation of reactive oxygen species (ROS), leading to oxidative damage to cellular components, including lipids, proteins, and DNA. This oxidative stress can enhance HIV replication by activating transcription factors such as nuclear factor-kappa B (NF-κB), which in turn stimulates the HIV long terminal repeat (LTR) promoter.

The dual nature of iron dysregulation in HIV infection presents challenges for clinical management.^27-28 On one hand, addressing iron deficiency and anemia is crucial for improving patient outcomes and quality of life. On the other hand, preventing and managing iron overload is essential to avoid further complications. Therapeutic strategies must therefore be carefully tailored to individual patients based on their iron status, the presence of co-infections, and the specific ART regimen being used. For HIV-infected patients with anemia, treatment options include erythropoiesis-stimulating agents (ESAs), iron supplementation, and managing underlying causes such as opportunistic infections or bone marrow suppression. Iron supplementation must be approached cautiously, as excessive iron can exacerbate oxidative stress and promote HIV replication. Monitoring of iron parameters, including serum ferritin and transferrin saturation, is essential to guide therapy.^29-31 In cases of iron overload, strategies may include reducing dietary iron intake, using iron chelation therapy, and optimizing ART regimens to minimize their impact on iron metabolism. Phlebotomy, commonly used in the treatment of hemochromatosis, may also be considered to reduce iron levels. Antioxidant therapy to mitigate oxidative stress is another potential approach, though further research is needed to establish its efficacy in the context of HIV infection. The interaction between HIV and iron homeostasis also has implications for the progression of liver disease, particularly in patients co-infected with hepatitis viruses. Iron overload can accelerate liver fibrosis and increase the risk of hepatocellular carcinoma, complicating the management of HIV-associated liver disease. Regular monitoring of liver function and iron levels, along with appropriate antiviral and iron-reducing therapies, is essential in these patients.

Impact of Iron Overload on HIV Progression

Iron overload, a condition characterized by excessive accumulation of iron in the body, can significantly influence the progression of HIV infection.³² This impact manifests through various mechanisms, including enhanced viral replication, immunosuppression, and increased oxidative stress.  Iron is essential for the replication of many viruses, including HIV. The virus relies on iron-dependent enzymes for its replication cycle. Iron overload provides a surplus of these necessary co-factors, facilitating more efficient viral replication. Studies have shown that elevated iron levels can enhance HIV replication in vitro by increasing the activity of reverse transcriptase, an iron-dependent enzyme crucial for converting viral RNA into DNA.^33-34 This increased replication rate can lead to higher viral loads in patients, accelerating disease progression and increasing the likelihood of transmission. Excessive iron can suppress the immune response, further compromising the already weakened immune system of HIV-infected individuals.³⁵ Iron overload can impair the function of various immune cells, including macrophages, dendritic cells, and lymphocytes. For instance, macrophages overloaded with iron have reduced capacity to present antigens and produce reactive oxygen species (ROS) necessary for killing pathogens. This immunosuppressive effect of iron can exacerbate the immunodeficiency caused by HIV, making patients more susceptible to opportunistic infections and decreasing their ability to control viral replication. One of the most detrimental effects of iron overload is the generation of oxidative stress. Excess iron catalyzes the formation of ROS through Fenton and Haber-Weiss reactions, leading to oxidative damage to cellular components such as lipids, proteins, and DNA. In HIV-infected individuals, oxidative stress is already elevated due to chronic inflammation and the virus's direct effects on cells. Iron overload can exacerbate this oxidative stress, contributing to cellular damage and apoptosis. Additionally, oxidative stress can activate transcription factors such as nuclear factor-kappa B (NF-κB), which in turn enhances the transcription of the HIV genome, further promoting viral replication.

Iron overload can also contribute to the progression of liver disease in HIV-infected individuals.³⁶ Many patients with HIV are co-infected with hepatitis B or C viruses, which also utilize iron for replication and can cause iron accumulation in the liver. Iron overload in the liver accelerates fibrosis and increases the risk of developing hepatocellular carcinoma. This is particularly concerning for HIV-infected patients, who are already at higher risk for liver complications due to chronic viral hepatitis and the hepatotoxic effects of some antiretroviral drugs.^37-39 Managing iron overload in HIV-infected individuals involves a multifaceted approach. Regular monitoring of iron levels, including serum ferritin and transferrin saturation, is essential to detect and address iron overload early. Phlebotomy, the process of removing blood to reduce iron levels, is a common treatment for hemochromatosis and can be beneficial for HIV-infected patients with iron overload. Iron chelation therapy, using agents such as deferoxamine, can also help remove excess iron from the body.^40-42 Additionally, optimizing antiretroviral therapy (ART) regimens to minimize their impact on iron metabolism is crucial. Some ART drugs can influence iron homeostasis, and selecting medications with minimal effects on iron levels may help manage iron overload. Antioxidant therapy, aimed at reducing oxidative stress, may also be beneficial, although more research is needed to establish its efficacy in this context.^43-45

Clinical Implications

The intersection of iron overload and HIV infection has several important clinical implications that impact both the management of HIV and the overall health of affected individuals. Addressing these implications requires a multifaceted approach to optimize patient outcomes and prevent complications associated with both conditions.⁴⁶ Regular monitoring of iron levels is crucial for HIV-infected patients, particularly those with a history of conditions that may predispose them to iron overload. Key tests include serum ferritin, transferrin saturation, and, in some cases, liver biopsy or imaging studies such as MRI to assess the extent of iron accumulation. Early detection of iron overload allows for timely intervention, potentially preventing severe complications associated with excessive iron, such as organ damage and increased oxidative stress.^46-47 Treatment strategies for managing iron overload in HIV-infected individuals vary based on the severity of the condition. Phlebotomy, which involves the removal of blood to reduce iron levels, is effective for patients with significant iron overload. However, it may not be suitable for all patients, particularly those with anemia or other contraindications. In such cases, iron chelation therapy using agents like deferoxamine or deferasirox can be used to bind excess iron and promote its excretion. The choice of treatment should be tailored to the individual’s specific needs and overall health status.⁴⁸

Antiretroviral therapy (ART) plays a crucial role in managing HIV infection and can also influence iron metabolism.⁴⁹ Some ART drugs may have effects on iron absorption and utilization, potentially exacerbating iron overload or contributing to anemia. Clinicians must carefully select ART regimens to balance effective viral suppression with minimal impact on iron homeostasis. Regular monitoring of blood counts and iron parameters should be part of routine care for patients on ART to detect and address any emerging issues related to iron metabolism. Anemia is a common complication in HIV-infected individuals and can be exacerbated by iron overload or deficiency.⁵⁰ Treatment of anemia may involve erythropoiesis-stimulating agents (ESAs), iron supplementation, or addressing underlying causes such as opportunistic infections or bone marrow suppression. When prescribing iron supplements, it is essential to assess the patient's iron levels to avoid exacerbating iron overload. Proper management of anemia improves patient well-being and enhances response to ART. HIV-infected patients are often co-infected with other viruses, such as hepatitis B or C, which can further complicate iron metabolism and liver health.⁵¹ Iron overload can accelerate liver fibrosis and increase the risk of hepatocellular carcinoma in these patients. A comprehensive management plan should include regular monitoring of liver function and iron levels, along with appropriate antiviral therapies to manage co-infections and prevent liver damage. Dietary management is an important aspect of controlling iron levels. Patients should be advised to limit dietary sources of iron, particularly heme iron from animal products, and avoid iron supplements unless prescribed. Additionally, avoiding excessive vitamin C intake is recommended, as it enhances iron absorption. Educating patients on dietary modifications can help manage iron levels and reduce the risk of complications. Given the role of oxidative stress in exacerbating HIV progression and iron overload, antioxidant therapy may offer potential benefits. Antioxidants can help mitigate oxidative damage caused by excess iron and chronic inflammation. However, more research is needed to determine the efficacy and safety of antioxidant supplementation in HIV-infected individuals with iron overload. Managing iron overload in HIV-infected patients requires a multidisciplinary approach involving primary care physicians, infectious disease specialists, hematologists, and other healthcare providers. Coordination among specialists ensures that all aspects of patient care are addressed, including managing HIV, iron levels, anemia, and potential complications. Regular follow-ups and comprehensive care are essential for optimizing patient outcomes. Educating patients about the impact of iron overload on their health and the importance of adherence to prescribed treatments is vital. Patients should be informed about the symptoms of iron overload, the need for regular monitoring, and the potential side effects of treatments. Adherence to therapy and lifestyle modifications can significantly improve management outcomes and overall quality of life.

Conclusion

The interplay between iron overload and HIV infection presents significant clinical challenges that impact disease progression, management, and patient outcomes. Iron overload can exacerbate HIV progression through mechanisms such as increased viral replication, enhanced oxidative stress, and immunosuppression. These effects underscore the importance of understanding and addressing the complex relationship between iron metabolism and HIV to optimize patient care. Effective management of iron overload in HIV-infected individuals requires a multifaceted approach that includes regular monitoring of iron levels, appropriate therapeutic interventions, and careful selection of antiretroviral therapies. Phlebotomy and iron chelation therapy are key treatments for reducing excess iron, while optimizing ART regimens helps balance effective viral suppression with minimal impact on iron metabolism. Addressing anemia and co-infections, particularly hepatitis viruses, is also crucial for comprehensive patient care. Dietary and lifestyle modifications play an essential role in managing iron levels and improving patient outcomes. Educating patients about the impact of iron overload and the importance of adherence to prescribed treatments and lifestyle changes is vital for effective disease management.

References

1. Halliday JW, Powell LW. Hemochromatosis and other diseases associated with iron overload. InIron and human disease 2018: 131-160. CRC press. https://doi.org/10.1201/9781351073899-5

2. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).

3. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41

4. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

5. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64

6. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16

7. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32

8. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36

9. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.

10. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26

11. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

12. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35

13. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59

14. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57

15. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15

16. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72

17. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

18. Obeagu EI. Iron Overload in HIV: Impact on Hepatic Function. Elite Journal of Nursing and Health Science. 2023;1(1):24-38. https://doi.org/10.22270/ajdhs.v4i1.63

19. Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. Journal of Trace Elements in Medicine and Biology. 2012;26(2-3):115-119. https://doi.org/10.1016/j.jtemb.2012.03.015 PMid:22575541

20. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012;1823(9):1434-1443. https://doi.org/10.1016/j.bbamcr.2012.01.014 PMid:22306005 PMCid:PMC4048856

21. Sundic T, Hervig T, Hannisdal S, Assmus J, Ulvik RJ, Olaussen RW, Berentsen S. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis. Blood Transfusion. 2014;12(Suppl 1):s84.

22. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63

23. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17

24. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35

25. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24

26. Ellis RJ, Marquine MJ, Kaul M, Fields JA, Schlachetzki JC. Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nature Reviews Neurology. 2023;19(11):668-687. https://doi.org/10.1038/s41582-023-00879-y PMid:37816937 PMCid:PMC11052664

27. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937. https://doi.org/10.1097/MD.0000000000036937 PMid:38215133 PMCid:PMC10783375

28. Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine. 2024;2(5):36-52.

29. Obeagu EI. Current Insights into Erythropoietin Levels and Anemia in HIV Patients. Elite Journal of Haematology, 2024; 2 (6).:35-45.

30. Obeagu EI, Obeagu GU. Erythropoietin Signaling and its Implications in HIV-Related Anemia: A Comprehensive Review. Elite Journal of HIV. 2024;2(4):54-71.

31. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.

32. Obeagu EI. Iron Overload in HIV: Impact on Hepatic Function. Elite Journal of Nursing and Health Science. 2023;1(1):24-38. https://doi.org/10.22270/ajdhs.v4i1.63

33. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nature Reviews Microbiology. 2008;6(7):541-552. https://doi.org/10.1038/nrmicro1930 PMid:18552864

34. Liu W, Zhang S, Nekhai S, Liu S. Depriving iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Current clinical microbiology reports. 2020; 7:13-19. https://doi.org/10.1007/s40588-020-00140-w PMid:32318324 PMCid:PMC7169647

35. Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Journal of Immunology Research. 2012;2012(1):784740. https://doi.org/10.1155/2012/784740 PMid:22242039 PMCid:PMC3254022

36. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

37. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

38. Obeagu EI. Iron Overload in HIV: Implications for Antiretroviral Therapy. Elite Journal of Health Science. 2023;1(1):25-37.

39. Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV. 2024;2(6):1-2.

40. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.

41. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.

42. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.

43. Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine. 2024;2(5):36-52.

44. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.

45. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.

46. Obeagu EI. Current Insights into Erythropoietin Levels and Anemia in HIV Patients. Elite Journal of Haematology, 2024; 2 (6).:35-45.

47. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. Elite Journal of Haematology, 2024; 2 (4). 2024:51-67.

48. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

49. da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World journal of virology. 2015;4(2):56. https://doi.org/10.5501/wjv.v4.i2.56 PMid:25964872 PMCid:PMC4419122

50. Bain BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Current opinion in hematology. 1999;6(2):89. https://doi.org/10.1097/00062752-199903000-00006 PMid:10088638

51. Shahriar S, Araf Y, Ahmad R, Kattel P, Sah GS, Rahaman TI, Sadiea RZ, Sultana S, Islam MS, Zheng C, Hossain MG. Insights into the coinfections of human immunodeficiency virus-hepatitis B virus, human immunodeficiency virus-hepatitis C virus, and hepatitis B virus-hepatitis C virus: Prevalence, risk factors, pathogenesis, diagnosis, and treatment. Frontiers in microbiology. 2022; 12:780887. https://doi.org/10.3389/fmicb.2021.780887 PMid:35222296 PMCid:PMC8865087